Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 TherapyL. Dousset, Lise Boussemart, Émilie Routier et al.|JCO Precision Oncology|2021Cited by 61
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 studyCaroline Robert, Alexander C. J. van Akkooi, Michal Kiciński et al.|The Lancet Oncology|2025Cited by 10
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced <i>BRAF</i>-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).Caroline Robert, Alexander Christopher Jonathan Van Akkooi, Caroline Dutriaux et al.|Journal of Clinical Oncology|2024Cited by 8